Graphene Sensors May Help to Detect Sepsis Earlier in Critically Ill Patients

A new study from the University of Bath has shown that graphene-based biosensors, designed by Integrated Graphene, have the potential to play a major role in detecting increased levels of lactate, an important biomarker for the treatment of critically ill patients.

The research, published in Sensor and Actuators: B.Chemical1, shows that Integrated Graphene’s Gii-Sens™ electrochemical sensor can improve accuracy in the diagnosis of hyperlactatemia, a common complication in intensive care units.

Hyperlactatemia results from a lack of oxygen reaching tissues or as a result of an underlying condition, such as advanced liver disease. Untreated hyperlactatemia can lead to lactate acidosis, which causes severe illness and can be fatal. Reliable real-time lactate detection through single-point or continuous monitoring could help to improve the outcomes of patients in critical care and could hasten the diagnosis of sepsis in critically ill patients.

Based in Stirling, Integrated Graphene’s flagship product, Gii-Sens™ is a biosensing electrode for diagnostics which outperforms traditional sensing materials by 10-100 times, allowing for cost effective, lab precision testing within minutes at the point of need. Other applications of the technology include quality control in the food production industry, and wearable lactate sensors which can be used to monitor an athlete’s performance in real time.

Dr Marco Caffio, Integrated Graphene’s Co-Founder and CSO, said: “Lactate is a naturally occurring biomarker which everyone produces as a byproduct of exercising. For most people it is easily processed by the body and will cause no major harm, apart from a little cramp if you overexert yourself.

“However, for some critically ill patients and those with underlying conditions it can be a sign of a range of other issues, some of which, like sepsis, can be fatal. Having a robust way of monitoring lactate levels is important in ensuring the best possible outcomes for these patients. The findings of this study demonstrate Gii’s reliable performance and potential to save lives.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”